Abstract
This study examines a new tumour marker, Cyfra 21-1, as a prognostic marker in predicting the survival of H&N cancer patients, and its correlation with clinical outcome during prolonged follow up of these patients. The study included 67 patients with primary detection of carcinoma of H&N. The survival of these patients was evaluated in correlation with the disease stage and Cyfra 21-1 levels at initial diagnosis. 38 patients were followed clinically and with serial assays for at least 12 months, or until recurrence was diagnosed. Cyfra 21-1 levels were determined periodically, using an Elisa kit. Patients with Cyfra 21-1 < 1.5 ng ml–1had a higher survival rate compared to patients with Cyfra 21-1 ≥ 1.5 ng ml–1(63% vs. 20%, respectively). The risk ratio of Ln(Cyfra 21-1) is 1.62 (P = 0.028). In a Cox regression model that included the disease stage and Ln(Cyfra 21-1), Ln(Cyfra 21-1) was preferred as the main parameter for predicting patients survival. In 83% of the 12 patients with recurrent or residual disease, Cyfra 21-1 was elevated before or during clinical detection of the recurrence. Cyfra 21-1 was found to be a prognostic marker for carcinoma of H&N, unrelated to the stage of the disease. Elevated levels of Cyfra 21-1 without clinical evidence of disease can be attributed to the marker's mean lead-time as compared to the clinical appearance of the disease. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bodenmuller H, Banauch D, Ofenloch B, Jaworek D and Dessauer A (1992) Cancer of the breast – state and trends in diagnosis and therapy. In: Klapdor R (ed) Technical evaluation of a new automated tumour marker assay: the enzymun-test Cyfra 21-1. Tumour Associated Antigens, Oncogenes, Receptors, Cytokines in Tumour Diagnosis and Therapy at the Beginning of the Nineties. W Zuckschwerdt Verlag Munchen, Bern, Wien, pp 137–138
Bonfrer JMG, Gaarenstroom KN, Kenter GG, Korse CM, Hart AAM, Gallee MPW, Helmerhorst TJM and Kenemans P (1994) Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecologic Oncology 55: 371–375
Calsen B, Pere P, Senekowitsch R and Menz E (1990) SCC as a tumor marker in the initial diagnosis of carcinoma of the head and neck region. Laryngorhinootologie 65: 275–280
Daver A, Dalifard I, Pns-Anicet D, Krebs BP, Gosselin P, Cazin JL, Ricolleau G, Gaillard G and Gachon F Goussard J (1990) Diagnostic value of SCC-TA4 determination in four localization of epidermoid cancer: an experience of the FNCLCC subgroup of radio-analysis. Bull Cancer 77: 781–792
Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M and Gruener N (1995) Cyfra 21-1 a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121: 177–181
Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T and Bombardieri E (1994) Cytokeratin 19 fragment Cyfra 21-1 compared to carcinoembrionic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Result of an international multicentric study. Eur J Clin Chem Clin Biochem 32: 189–199
Ebert W, Bodenmuller H and Holzel W (1995) Cyfra 21-1 – clinical application and analytical requirements. Scan J Clin Lab Invest 55: 72–80
Fichbach N, Meyer T and Barthel K (1990) Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma. Cancer 65: 1321–1324
Hoefler H and Denk H (1984) Immunohistochemical demonstration of cytokeratin in gastrointestinal carcinoids and their probable precursors cells. Virchows Arch. B. Cell Pathol 403: 235–240
Katopodis N, Hishaut Y, Geller NL and Stock CC (1982) Lipid associated sialic acid test for the detection of human cancer. Cancer Res 42: 5270–5275
Martin M, Rayo JI, Talavera JR, Munoz A and Cazino A (1990) Evaluation of serum tumor markers in the head and neck cancer. J Nucl Med Allied Sci 34: 235–238
Maxim PE, Veltri RW, Sprinkle PM and Pusater RJ (1978) Soluble immune complexes in sera from head and neck cancer patients: a preliminary report. Otolaryngology 86: 428–432
Moll R, Franke WW, Schiller DL, Geiger B and Krepler R (1982) The catalogue of human cytokeratin: pattern of expression in normal epithelia, tumors and cultured cells. Cell 31: 11–24
Nakata T, Chung YS, Kato Y, Ogawa Y, Inui A, Maeda K, Sawada T and Sowa M (1996) Clinical significance of serum Cyfra 21-1 in gastric cancer. Br J Cancer 73: 1529–1532
Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F and Laudanski J (1995) Diagnostic and prognostic value of the new tumour marker Cyfra 21-1 in patients with squamous cell lung cancer. Eur Respir J 8: 291–294
Niklinski J, Furman M, Burzykowski T, Chyczewski L, Laudanski J, Chyczewska E and Rapellino M (1996) Preoperative Cyfra 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 74: 956–960
Ogawa T, Tsutusako Y, Kimura N, Nishioka S, Akagi H, Nishizaki K, Nishioka K and Rutka J (1999) Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngolo Suppl (Stockh) 540: 72–76
Osborn M and Weber K (1982) Intermediate filaments: cell-type-specific markers in differentiation and pathology. Cell 31: 303–306
Plermo F, Carniato A, Fede A, Boccaletto F and Marchiori C (1990) Serum SCC antigen in head and neck squamous cell carcinoma. Int J Biol Markers 5: 118–120
Pujol JL, Grenier J, Daures JP, Daver A, Pujol H and Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61–66
Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X and Michel FB (1996) Cytokeratin as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am J Respir Crit Care Med 154: 725–733
Rastel D, Ramaioli A, Cornillie F and Thirion B (1994) Cyfra 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European Multicenter Evaluation. Eur J Cancer 30A: 601–606
Ropka ME, Goodwin WJ, Levine PA, Sasaki CT, Kirchner JC and Cantrell RW (1991) Effective head and neck tumor markers. Arch Otolaryngol Head Neck Surg 117: 1011–1014
Shideler CE, Johns ME and Cantrell RW (1981) Erythrocyte polyamine determination in patients with head and neck cancer. Arch Otolaryngol 107: 752–754
Silverman NA, Alexander JC and Chretien PB (1976) CEA levels in head and neck cancer. Cancer 37: 2204–2211
Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W and Fateh-Moghadam A (1993) Cyfra 21-1 a new marker in lung cancer. Cancer 7: 707–713
Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F and Splinter TAW (1994) Evaluation of a new tumor marker in patients with non-small-cell lung cancer: Cyfra 21-1. Br J Cancer 69: 525–528
Walther EK, Dahlmann N and Gorgulla HT (1990) Tumor markers in patients with head and neck carcinoma. Laryngorhinootologie 69: 271–274
Wolf GT, Chretien PB and Elias EG (1979) Serum glycoproteins in head and neck squamous carcinoma. Am J Surg 138: 489–500
Yen TC, Lin WY, Kao CH, Cheng KY and Wang SJ (1998) A study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 23: 82–86
Yoshimura Y, Oka M and Harada T (1990) SCC-antigen for detection of squamous cell and mucoepidermoid carcinoma after primary treatment: a preliminary report. J Oral Maxillofac Surg 48: 1288–1292
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Doweck, I., Barak, M., Uri, N. et al. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83, 1696–1701 (2000). https://doi.org/10.1054/bjoc.2000.1502
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1502
Keywords
This article is cited by
-
Determinants of the level of circulating-tumor HPV16 DNA in patients with HPV-associated oropharyngeal cancer at the time of diagnosis
Scientific Reports (2023)
-
Clinical relevance of CYFRA 21-1 as a tumour marker in patients with oropharyngeal squamous cell carcinoma
European Archives of Oto-Rhino-Laryngology (2020)
-
CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
European Archives of Oto-Rhino-Laryngology (2019)
-
Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples
Analytical and Bioanalytical Chemistry (2017)
-
Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma
Tumor Biology (2016)